These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11228623)

  • 1. Entry inhibitor combination shows promise.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11228623
    [No Abstract]   [Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
    Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
    J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV fusion and its inhibition.
    LaBranche CC; Galasso G; Moore JP; Bolognesi DP; Hirsch MS; Hammer SM
    Antiviral Res; 2001 May; 50(2):95-115. PubMed ID: 11369431
    [No Abstract]   [Full Text] [Related]  

  • 4. Resistance to HIV-1 entry inhibitors.
    Olson WC; Maddon PJ
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):283-94. PubMed ID: 14754430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20).
    Zhang XQ; Sorensen M; Fung M; Schooley RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2231-3. PubMed ID: 16723592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [T-20: a fusion inhibitor].
    Iafolla M
    Sidahora; 2002; (3):20-2. PubMed ID: 12703471
    [No Abstract]   [Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
    Ketas TJ; Frank I; Klasse PJ; Sullivan BM; Gardner JP; Spenlehauer C; Nesin M; Olson WC; Moore JP; Pope M
    J Virol; 2003 Feb; 77(4):2762-7. PubMed ID: 12552019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140).
    Shearer WT; DeVille JG; Samson PM; Moye JH; Fletcher CV; Church JA; Spiegel HM; Palumbo P; Fenton T; Smith ME; Graham B; Kraimer JM; Olson WC
    J Allergy Clin Immunol; 2006 Aug; 118(2):518-21. PubMed ID: 16890780
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV genetic mutations causing resistance to the new drug T-20: recent findings.
    Bean P
    Am Clin Lab; 2002 Oct; 21(8):15-6. PubMed ID: 12440170
    [No Abstract]   [Full Text] [Related]  

  • 10. What's taking T-20 so long?
    Huff B
    GMHC Treat Issues; 2001 Apr; 15(4):1-3. PubMed ID: 11590938
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
    van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
    Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor.
    Ji C; Zhang J; Dioszegi M; Chiu S; Rao E; Derosier A; Cammack N; Brandt M; Sankuratri S
    Mol Pharmacol; 2007 Jul; 72(1):18-28. PubMed ID: 17392523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
    Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
    Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs show promise in attacking HIV.
    Dent Today; 2002 Dec; 21(12):30. PubMed ID: 12572158
    [No Abstract]   [Full Text] [Related]  

  • 17. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
    Rusert P; Kuster H; Joos B; Misselwitz B; Gujer C; Leemann C; Fischer M; Stiegler G; Katinger H; Olson WC; Weber R; Aceto L; Günthard HF; Trkola A
    J Virol; 2005 Jul; 79(13):8454-69. PubMed ID: 15956589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
    Barretina J; Blanco J; Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
    Antivir Ther; 2003 Apr; 8(2):155-61. PubMed ID: 12741628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
    ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
    [No Abstract]   [Full Text] [Related]  

  • 20. Progress in targeting HIV-1 entry.
    Ryser HJ; Flückiger R
    Drug Discov Today; 2005 Aug; 10(16):1085-94. PubMed ID: 16182193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.